Extract Amyda sinensis raised the levels of Plasma proteins. Plasma albumin was raised from 2.67?0.44 to 3.25?0.34g/dl and the total Plasma protein from 5.34?0.88 to 6. 74 ?1. 38 /dl. 3H-TdR and .3H-Leucine incorporation techniques were used to measure the syntheses rate of DAN and protein .The rates was accelerated.The specifie activities of DNA and protein of liver got up to 3.90?1.41 from 2.42?0.71 dpm/?g, and 21.69?4.84 from 12.81 ?5.83 dpm/?g, respectively.Those of spleen got up to 41.88?18.47 from 19.04?10.54 dpm/?g and 23.12?4.38 from 16.34?7.01 d pm/?g, respectively. Extract Amyda sinensis had no effect on DNA synthesis of bone marrow cells and did not raise the hemoglobin level in mice. The results suggest that Extract Amyda sinensis has bioactive substance that accelcrate synthcses of DNA and protein.

Objective To observe the clinical efficacy of thread embedding at Back-Shu points in treating stroke-associated pneumonia.Method Seventy patients with stroke-associated pneumonia were randomized into a treatment group and a control group, 35 cases in each group. The control group was intervened by regular medications, while the treatment group was additionally intervened by thread embedding at the Back-Shu points. Before and after the intervention, C-reactive protein (CRP), white blood cell (WBC), neutrophil ratio (NE%), and symptoms and signs scores were observed, and the clinical efficacies were compared between the two groups.Result The CRP, WBC, NE%, and symptoms and signs scores were significantly changed after intervention in both groups (P<0.05). After intervention, the CRP, WBC, NE%, and symptoms and signs scores in the treatment group were significantly different from that in the control group (P<0.05). The total effective rate was 91.4% in the treatment group, versus 82.9% in the control group, and the difference was statistically significant (P<0.05).Conclusion Thread embedding at the Back-Shu points can promote the treatment of stroke-associated pneumonia.

Objective To compare the difference of the clinical efficacy on post-stroke shoulder-hand syndrome treated by acupuncture at stellate ganglion and by conventional acupuncture. Methods Ninety cases of post-stroke shoulder-hand syndrome ( at stageⅠ or stageⅡ) were randomized into treatment group and control group, 45 cases in each group. Both groups received basic rehabilitation training. Additionally, the treatment group received acupuncture at the bilateral stellate ganglions of the neck, with reducing acupuncture by rotating the needles. The control group received the conventional acupuncture on Jiquan ( HT 1) , Chize ( LU 5) , Jianyu (LI 15), Quchi (LI 11), Shousanli (LI 10), Hegu (LI 4), with reducing acupuncture by lifting and thrusting the needle on Jiquan ( HT 1) and Chize ( LU 5) , and with mild reinforcing and reducong acupuncture on the other acupoints. The treatment for both groups was given once every day, and 14 times in total. The total syndrome scores, visual analogue scale (VAS) scores, modified Fugl-Meyer Assessment of motor function scale (FMA) scores, and modified Barthel index (MBI) were observed to evaluate the changes of symptoms, pain and motor function of the upper limbs, and activity of daily life before and after treatment in the two groups. The clinical efficacy was also compared between the two groups. Results The total syndrome scores, VAS scores, FMA scores and the modified Barthel index were improved apparently after treatment in the two groups (all P<0.01), and the improvement in the treatment group as more obvious (all P<0.01) . The total effective rate was 93.33% (42/45) in the treatment group, which was better than 73.33% (33/45) in the control group ( P<0.05) . During the treatment, patients of both groups had good compliance, and all completed the trial. No obvious adverse reaction was found in the two groups. Conclusion Acupuncture at stellate ganglion is effective and safe for the treatment of post-stroke shoulder-hand syndrome, and it has higher efficiency than the conventional acupuncture.

[Ab]stract] Objective To investigate, according to core myodynamic theory, the clinical efficacy of electroacupuncture at Huatuo jiaji points in treating motor dysfunction in stroke patients during the flaccid paralysis stage.Methods Sixty stroke patients in the stage of flaccid paralysis were randomly allocated to treatment and control groups, 30 cases each. The control group received basic treatment and conventional acupuncture and the treatment group, electroacupuncture at Huatuo jiaji points in addition. The simplified Fugl-Meyer assessment (FMA) score and the Modified Barthel Index (MBI) score were counted before and after treatment and the clinical therapeutic effects were compared between the two groups.Results There were statistically significant pre-/post-treatment differences in the FMA score and the MBI score in the two groups (P<0.05). There were statistically significant post-treatment differences in the FMA score and the MBI score between the treatment and control groups (P<0.05). The total efficacy rate was 96.7% in the treatment group and 86.7% in the control group; there was a statistically significant difference between the two groups (P<0.05).Conclusion Electroacupuncture at Huatuo jiaji points has a promoting effect on the rehabilitation of limb function in the flaccid paralysis stage of stroke.

Objective: To analyze the mutation of autoimmune regulator ( AIRE ) gene in a pedigree with autoimmune polyendocrine syndrome type Ⅰ (APS-Ⅰ). Methods: The peripheral blood samples from family members were collected for DNA extraction, and then the mutation sites on AIRE gene were screened by PCR and Sanger sequencing. The mutation sites were further verified in 100 healthy persons by the created restriction site PCR (CRS-PCR) and PCR restriction fragment length polymorphism (PCR-RFLP). The effects of mutation on the structure and function of AIRE protein were analyzed with SIFT, PolyPhen-2, Mutation Taster and Antheprot Editor softwares. The effects of mutation on the splicing sites of AIRE mRNA were predicted with Alternative Splice Site Predictor, FruitFly Splice Predictor and SplicePort softwares, and further verified by Sanger sequencing. Results: Two novel heterozygous mutations c.47 C＞G T16R and c.1631-2 A＞T were found in the proband. The c.47 site is highly conserved and homologous in different species. The missense mutation of c.47C＞G changed the secondary structure and hydrophobicity of AIRE protein, and affected its function. The c.1631 -2 A＞T mutation changed the splicing site of AIRE mRNA, and led to the deletion of exon 13. Conclusion Two novel pathogenic mutations c.47 C＞G T16R and c.1631-2 A＞T are identified in a pedigree with autoimmune polyendocrine syndrome type Ⅰ.